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Abstract
Objective
To assess efficacy and safety of dual therapy (DT) and triple therapy (TT) in patients with atrial
fibrillation (AF) and acute coronary syndrome (ACS) with or without percutaneous coronary
intervention (PCI) and evaluate the quality of evidence with respect to said outcomes based on
contemporary randomized trials (RCTs). The efficacy outcome taken was major adverse
cardiovascular events (MACE) while safety outcome was major bleeding events.
Introduction
Appropriate anti-thrombotic therapy is still controversial in patients with AF and concomitant
ACS or PCI. We conducted a conventional meta-analysis pooling data from major RCTs to assess
the efficacy and safety of DT and TT. Additionally, we utilized advanced analytic properties of
trial sequential analysis (TSA) to assess for quality of evidence in this realm.
Methods and results
A total of 8,732 patients from five major RCTs were enrolled in this study. There was a
statistically significant reduction in major bleeding on the DT group compared to the TT group
(RR 0.65, 95% CI 0.48, 0.86). The incidence of major adverse cardiovascular events (MACE) was
similar in both groups (RR 0.97, 95% CI 0.8,1.17). The trial sequential analysis showed strong
evidence supporting reduction in bleeding from current major RCTs while being inconclusive
based on MACE outcome.
Conclusion
Sufficient quality evidence could be ascertained from contemporary RCTs on reduced incidence
of bleeding in DT patients compared to TT patients. Further adequately powered RCTs are
needed to ensure non-inferiority of DT over TT with respect to MACE outcome.
Categories: Cardiology, Quality Improvement
Keywords: dual therapy, triple therapy, meta-analysis, atrial fibrillation, acute coronary syndrome
1 1 2 1 1
 Open Access OriginalArticle  DOI: 10.7759/cureus.4880
How to cite this article
Munir M B, Osman K, Saleem M, et al. (June 11, 2019) Trial Sequential Analysis Comparing Bleeding and
Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on
Dual versus Triple Therapy. Cureus 11(6): e4880. DOI 10.7759/cureus.4880
Introduction
The management of patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or
percutaneous coronary intervention (PCI) continues to be challenging in term of
antithrombotic therapy choice. Triple therapy (TT) with an oral anticoagulant and dual
antiplatelet medications is currently endorsed as the therapy of choice by the European
guidelines in this patient population [1]. In contrast, North American guidelines recommend
dual therapy (DT) with new oral anticoagulant and P2Y12 inhibitor [2]. 
We used the advanced meta-analytic properties of trial sequential analysis (TSA) to assess the
quality of available evidence comparing TT vs. DT from current major randomized controlled
trials (RCTs). For the purpose of our analysis, we used major adverse cardiovascular events
(MACE) as an efficacy outcome while major bleeding was taken as a safety outcome.
Materials And Methods
For the current study, data was pooled from five major RCTs that compared DT and TT in AF
patients with associated ACS and/or PCI. The RCTs used to collect data for our current analysis
included the recently published Open-label, 2x2 Factorial, Randomized Controlled, Clinical
Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin
Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous
Coronary Intervention (AUGUSTUS) trial [3] and previously published Randomized Evaluation
of Dual Antithrombotic Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients
With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (RE‐DUAL
PCI) trial [4], Open-Label, Randomized, Controlled, Multicenter Study Exploring Two
Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist
Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary
Intervention (PIONEER-AF PCI) trial [5], Intracoronary Stenting and Antithrombotic Regimen-
Testing of a 6-Week Versus a 6-Month Clopidogrel Treatment Regimen in Patients With
Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eluting Stenting (ISAR-
TRIPLE) trial [6], and What is the Optimal Antiplatelet and anticoagulant therapy in patients
with oral anticoagulation and coronary StenTing (WOEST) trials [7]. The relevant data was
collected into Microsoft Excel worksheet. For the purpose of our analysis, we extracted data
from patients on 150 mg of dabigatran twice a day from RE-DUAL PCI trial and on 15 mg
rivaroxaban daily from PIONEER AF trial. Since our study contained pooled patient data from
these RCTs, the need for institutional review board was deferred.
TSA can be applied to quantify the reliability of conclusions driven from meta-analysis by
establishing monitoring boundaries to test the quality of evidence. By this method, if the
cumulative Z curve crossed the TSA boundary, a sufficient level of evidence has been reached
supporting the intervention. However, if the Z curve failed to cross the TSA boundary, evidence
to reach a conclusion is insufficient and more studies are needed. We pooled the primary safety
outcome of bleeding (defined as Thrombolysis in Myocardial Infarction major and minor
bleeding) and the primary efficacy outcome of major adverse cardiovascular events (composite
of cardiac death, stent thrombosis, stroke and myocardial infarction) using the random effect
model from above RCTs comparing DT to TT at the maximum reported follow-up. We then
performed TSA to maintain an overall two-sided type-I error rate at 5% and calculated the
required sample size to achieve 80% power to detect a statistically significant difference. The
analysis was conducted using RevMan 5.3 (The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark) and Copenhagen Trial Unit, version 0.9.5.10 beta.
Limitations
Few limitations of our study should be acknowledged. We do not have patient-level data for our
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current meta-analysis and utilized trial-level data so we cannot account for differences in
baseline characteristics that may affect outcomes. Additionally, differential trial designs may
have instituted heterogeneity although we tried to mitigate this by depicting statistical
heterogeneity for each outcome studied.
Results
A total of five major RCTs with 8,732 patients were included in the current analysis. A
statistically significant reduction in the rate of bleeding was seen in the DT group compared to
the TT group (RR 0.65, 95% CI 0.48, 0.86) (Figure 1). The corresponding Z-curve successfully
crossed the conventional test boundary as well as the TSA monitoring boundary indicating firm
evidence supporting the lower rate of bleeding in DT (Figure 2). On the other hand, there was
no difference in MACE between the two groups (RR 0.97, 95% CI 0.8,1.17) (Figure 3). The MACE
Z-curve failed to cross the conventional and TSA test boundaries indicating that no firm
conclusion could be derived on the benefit of TT over DT in preventing MACE outcomes in
these patients (Figure 4).
FIGURE 1: Forest plot comparing bleeding events between
triple therapy (TT) and dual therapy (DT)
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FIGURE 2: Trial sequential analysis for bleeding events
The cumulative Z-curve (blue line with small black squares representing each trial) crosses both the
traditional (horizontal red line) and the trial sequential monitoring boundary (concave red line),
indicating firm evidence of better outcomes in the dual therapy group compared to the triple therapy.
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FIGURE 3: Forest plot comparing major adverse cardiovascular
events (MACE) between triple therapy (TT) and dual therapy
(DT)
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FIGURE 4: Trial sequential analysis for major adverse
cardiovascular events (MACE)
The cumulative Z-curve (blue line with small black squares representing each trial) failed to cross
both the traditional (horizontal red line) and the trial sequential monitoring boundary (concave red
line), indicating no difference between both groups and no sufficient evidence to meet the trial
sequential analysis (TSA) boundary.
Discussion
The findings from our current analysis indicate firm evidence supporting lower rates of
bleeding in patients treated with DT vs TT. Our conventional meta-analysis further showed that
TT confers no additional benefit in preventing MACE outcomes when compared to DT. TSA
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analysis, however, concluded that sufficient evidence could not be obtained with respect to
MACE outcomes among patients on DT and TT. The management of AF patients with
concomitant ACS or PCI is fraught with uncertainty. While oral anticoagulants are shown to be
superior to dual anti-platelet agents (DAPT) in reducing risk of ischemic stroke and systemic
embolism in AF patients, they don’t confer any benefit in preventing complications such as
stent thrombosis [8]. On the contrary, DAPT has shown to have superior efficacy in preventing
cardiovascular ischemic events and stent thrombosis but have not shown any benefit in
reducing embolic events in AF patients. The usual contemporary practice is to place these
patients on triple therapy which make them prone to significant bleeding complications. The
increased benefit of preventing MACE outcomes may be meager while on triple therapy. Our
analysis has shown a significant benefit of DT versus TT in reducing bleeding complications
with TSA endorsing sufficient evidence from current trials in supporting this conclusion. On the
contrary, our conventional meta-analysis did not show any statistically significant reduction in
MACE events with TT when compared to DT (RR 0.97, 95% CI 0.8,1.17). It is pertinent to point
out that advanced meta-analytical model of TSA concluded that no firm evidence could be
obtained with respect to MACE outcomes based on patients utilization of DT or TT.
Conclusions
Our conventional meta-analysis showed a significantly improved rate of bleeding in AF
patients with concomitant ACS and/or PCI on DT compared to TT while at the same time
showed similar incidence of MACE outcomes in both groups. TSA confirmed that sufficient
quality evidence exists from current RCTs that proves low incidence of bleeding in the DT
group compared to the TT group. However, more adequately powered RCTs are required to
ensure non-inferiority of DT over TT in preventing MACE related outcomes.
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